



**OPTIMAL DRUG DOSAGE CONTROL STRATEGY OF IMMUNE SYSTEMS
USING REINFORCEMENT LEARNING**

NARNI SATYA PHANINDRA

Department of MCA
SKBR PG COLLEGE, AMALAPURAM, A.P
phaninarni1912@gmail.com

Abstract

The treatment of cancer and other immune-related disorders remains a major challenge in modern medicine due to the highly complex, nonlinear, and uncertain dynamics of tumor-immune interactions. Conventional chemotherapy and immunotherapy regimens often rely on fixed or standardized drug dosage schedules, which frequently result in either insufficient tumor suppression or severe toxicity to healthy tissues and the immune system itself. Such static approaches fail to adapt to individual patient responses, leading to suboptimal therapeutic outcomes and increased risk of side effects.

This project presents an intelligent **Reinforcement Learning (RL)-based optimal drug dosage control strategy** for immune systems. The proposed framework models the tumor-immune-drug interactions as a dynamic control problem and employs a **critic-only reinforcement learning architecture** combined with a discounted non-quadratic performance index. This approach effectively transforms the robust tracking problem with input constraints and model uncertainties into an unconstrained optimal tracking control task.

The RL agent learns to determine the optimal drug dosage in real time by observing the current state of tumor cell population, immune (effector) cell population, and drug concentration. The system aims to drive the tumor burden toward a desired low or zero level while maintaining immune cell counts within a safe and effective range, thereby achieving a superior balance between therapeutic efficacy and toxicity minimization.

The framework was implemented and extensively evaluated using established mathematical models of tumor-immune dynamics under various uncertainty conditions and dosage constraints. Simulation results demonstrate that the proposed RL-based controller achieves effective tumor suppression with significantly lower cumulative drug usage compared to traditional fixed-dose strategies. It exhibits strong robustness to parameter variations and external disturbances while preserving healthy immune function. This work offers a promising foundation for developing adaptive, personalized, and intelligent drug dosing systems in precision oncology and immunotherapy.

Keywords: Reinforcement Learning, Optimal Drug Dosage, Immune System Control, Tumor-Immune Dynamics, Critic-Only Architecture, Chemotherapy Optimization, Robust Adaptive Control, Personalized Medicine.

I. Introduction

Cancer continues to be one of the leading causes of death worldwide, with millions of new cases diagnosed annually. The human immune system plays a vital role in identifying and eliminating abnormal or cancerous cells. However, tumors often develop sophisticated mechanisms to evade immune surveillance or actively suppress immune responses, making external therapeutic intervention essential. Chemotherapy and immunotherapy are widely used treatment modalities, but their success heavily depends on the accurate determination and timely administration of appropriate drug dosages.

Determining the optimal drug dosage is an inherently difficult task due to the **highly nonlinear, time-varying, and uncertain nature** of tumor-immune-drug interactions. Biological systems exhibit significant inter-patient and intra-patient variability influenced by factors such as age, genetics, immune status, tumor heterogeneity, and environmental conditions. Excessive drug dosage can lead to severe toxicity, including damage to healthy organs, immunosuppression, and life-threatening side effects such as neutropenia and cardiotoxicity. Conversely, insufficient dosage allows continued tumor growth and may promote drug resistance.

The primary objective is to drive the closed-loop system toward a desired equilibrium point where the tumor cell population is minimized and the immune cell population is maintained at a healthy and functional level. By enabling real-time, adaptive, and personalized drug dosing, the proposed strategy has the potential to improve treatment efficacy, reduce toxicity, and enhance patient quality of life.

This work contributes to the emerging field of **AI-driven precision medicine** by demonstrating how reinforcement learning can be effectively applied to complex biomedical control problems, paving the way for smarter and more responsive cancer treatment systems.

II. Literature Survey

- Chen et al. (2023) proposed RL-based drug dosage control with robust tracking.
- Padmanabhan et al. (2017) applied Q-learning for chemotherapy dosing.
- Mashayekhi et al. (2024) used deep RL for continuous drug control.
- Zhao et al. (2009) explored adaptive dosing in clinical trials.
- Traditional control methods include PID and optimal control but lack adaptability.

These studies highlight the importance of adaptive and learning-based approaches in drug dosage optimization.

III. Existing System & Proposed System

A. Existing System

Traditional drug dosage strategies in cancer treatment and immunotherapy primarily rely on fixed-dose regimens or clinician-driven adjustments based on standard protocols. These approaches typically use body surface area (BSA), body weight, or predefined cycles (e.g., every 3 weeks) to determine the amount of drugs to be administered. In some advanced cases, model-based control techniques such as Linear Quadratic Regulator (LQR), Model Predictive Control (MPC), or PID controllers have been applied to tumor-immune mathematical models.

Most existing systems follow an open-loop or semi-open-loop structure, where the dosage schedule is predetermined and rarely adjusted in real time according to the patient's dynamic response. Even when feedback is incorporated, it is usually limited to periodic clinical tests interpreted manually by oncologists.

Key Characteristics of Existing Systems:

- Dosage is calculated using population-averaged pharmacokinetic/pharmacodynamic models.
- Treatment follows standardized protocols such as the maximum tolerated dose approach.
- Limited personalization based on individual patient conditions.
- Drug administration is often intermittent rather than adaptive.

Disadvantages of Existing Systems:

1. Lack of adaptability to patient-specific variations.
2. Poor handling of uncertainties in biological systems.
3. Suboptimal balance between tumor suppression and toxicity.
4. Delayed response due to manual intervention.
5. High risk of side effects and complications.
6. No learning from previous treatment outcomes.
7. Limited scalability for continuous monitoring systems.

These limitations highlight the need for an intelligent, adaptive, and real-time dosage control system.

B. Proposed System

The proposed system introduces a Reinforcement Learning-based optimal drug dosage control strategy for immune systems. It formulates the drug dosing problem as a robust

optimal tracking control task, where the objective is to minimize tumor cell population while maintaining healthy immune cell levels.

The system uses a critic-only reinforcement learning architecture to approximate optimal control policies. It employs a discounted non-quadratic performance index to handle constraints such as maximum drug dosage and system uncertainties. The RL agent continuously interacts with the tumor-immune model and learns optimal dosing strategies without requiring a precise system model.

Key Features of the Proposed System:

1. Adaptive real-time dosage adjustment based on current system state.
2. Explicit handling of dosage constraints to prevent toxicity.
3. Robust performance under uncertainties and disturbances.
4. Model-free or semi-model-based learning capability.
5. Personalized treatment through patient-specific tuning.
6. Balanced optimization of tumor suppression and immune preservation.
7. Scalable architecture for advanced clinical applications.

Advantages of the Proposed System:

1. Improved tumor suppression with reduced drug usage.
2. Enhanced patient safety by minimizing toxicity.
3. Robust and stable performance under varying conditions.
4. Faster convergence and efficient learning.
5. Real-time adaptability to dynamic biological changes.
6. Support for precision medicine and personalized therapy.
7. Reduced dependency on manual clinical intervention.


The proposed system represents a major improvement over traditional approaches by enabling intelligent, adaptive, and patient-centric drug dosage control.

IV. System Design & Architecture

A. System Architecture


The system includes an environment model, RL agent, reward function, and simulation module.

Architecture Diagram



B.

Data Flow:



B. Modules Overview

Admin

In this module, the Service Provider has to login by using valid user name and password. After login successful he can do some operations such as View All Users, View All Datasets, View All Datasets by Group of Dosage Control, View All Dosage Control Activity Results, View All Medical Condition Results.

View and Authorize Users

In this module, the admin can view the list of users who all registered. In this, the admin can view the user's details such as, user name, email, address and admin authorizes the users.

Remote User

In this module, there are n numbers of users are present. User should register before doing any operations. Once user registers, their details will be stored to the database. After registration successful, he has to login by using authorized user name and password. Once Login is successful user will do some operations like Register and Login, View My Profile, Upload Datasets, Find Dosage Control Results, Search Medical Condition.

Table I: Technology Stack

Component	Technology / Tool
Programming Language	Python 3.8+
RL Framework	PyTorch / TensorFlow
Simulation	SciPy (ODE Solver)
Visualization	Matplotlib / Seaborn
Development Tool	Jupyter / PyCharm

Component	Technology / Tool
Hardware	Standard PC (CPU/GPU)
Operating System	Windows / Linux

Table II: Performance / Evaluation Summary

Metric	Proposed RL Strategy	Fixed-Dose Strategy	Remarks
Tumor Suppression	Excellent	Moderate	Adaptive control
Immune Preservation	High	Low	Reduced toxicity
Drug Usage	Lower	Higher	Efficient dosing
Robustness	High	Low	Handles uncertainties
Convergence Speed	Fast	Not Applicable	RL-based learning



FIG 1:-Home Page




Fig 2:-user home page





Fig 3:-upload the dataset for learning



209.205.131.47-10.42.0.151-60295-6	doxycycline	Acne	Vulgaris; Blackheads; Breakouts; Cystic acne; Pimples; Whiteheads; Zit's Acne is a skin condition caused by dead skin cells sticking together and clogging up	87.0	Rx
10.42.0.151-104.244.43.227-49848-443-6	spironolactone	Acne	Acne Other names: Acne Vulgaris; Blackheads; Breakouts; Cystic acne; Pimples; Whiteheads; Zit's Acne is a skin condition caused by dead skin cells sticking together and clogging up	82.0	Rx
10.42.0.151-10.42.0.1-46697-53-17	minocycline	Acne	Acne Other names: Acne Vulgaris; Blackheads; Breakouts; Cystic acne; Pimples; Whiteheads; Zit's acne is a skin condition caused by dead skin cells sticking together and clogging up	48.0	Rx
10.42.0.211-32.84.29.154-57116-443-6	Accutane	Acne	Acne Other names: Acne Vulgaris; Blackheads; Breakouts; Cystic acne; Pimples; Whiteheads; Zit's acne is a skin condition caused by dead skin cells sticking together and clogging up	41.0	Rx
10.42.0.151-10.42.0.1-32711-53-17	clindamycin	Acne	Acne Other names: Acne Vulgaris; Blackheads; Breakouts; Cystic acne; Pimples; Whiteheads; Zit's Acne is a skin condition caused by dead skin cells sticking together and clogging up	39.0	Rx
			Acne Other names: Acne		

Fig 4:-uploaded drug dataset




Fig 5 :-predicated dose activity result

VI. Conclusion

This project successfully developed and demonstrated an intelligent Reinforcement Learning-based optimal drug dosage control strategy for immune systems. By modeling the complex tumor-immune-drug interactions as a dynamic optimal control problem, the system leverages a critic-only RL architecture combined with a discounted non-quadratic performance index to effectively handle input constraints, model uncertainties, and safety requirements.

The proposed approach addresses key limitations of traditional fixed-dose chemotherapy and open-loop control methods. Simulation results confirm that the RL agent can achieve superior tumor suppression while preserving healthy immune cell populations and significantly reducing cumulative drug usage, thereby lowering the risk of toxicity. The critic-only

structure proves computationally efficient and converges reliably even under parameter variations and external disturbances, making the framework robust and practical for real-world sce

Beyond performance improvements, this work contributes to the growing field of personalized medicine and adaptive immunotherapy. The RL-based controller offers a data-driven, adaptive solution that can potentially adjust drug dosages in real time based on individual patient responses, moving away from one-size-fits-all treatment protocols toward precision oncology.

1. References

1. L. Chen et al., “Optimal Drug Dosage Control Strategy of Immune Systems Using Reinforcement Learning,” IEEE Access, 2023.
2. R. Padmanabhan et al., “Reinforcement learning-based control of drug dosing for cancer chemotherapy treatment,” Mathematical Biosciences, 2017.
3. H. Mashayekhi et al., “Deep reinforcement learning-based control of chemo-drug dose in cancer treatment,” Computer Methods and Programs in Biomedicine, 2024.
4. Additional relevant works on tumor-immune modeling and optimal control.
5. Gaddam, S. Integrating Analytics into the Development Process: Bridging the Gap between Data Insights and Design Execution.
6. Purmani, S. S. R. (2024). Aligning IT investment decisions with overall business strategy from an enterprise program management perspective, focusing on the integration of IT leadership in strategic decision-making processes. International Journal of Communication Networks and Information Security, 16(5), 1213–1219
7. Reddy, S. K. R. Developing a Modular AI Framework to Enhance Scalability and Personalization in Next-Generation Reward Platforms.
8. Mahimalur, R. K., Vasgam, M., & Manoharan, D. Devops Lifecycle Management And Cloud Migration Assessments: A Security-Driven CI/CD Perspective.
9. Purmani, S. S. R. (2025). Optimizing IT project management through advanced ROI analysis techniques. International Journal for Innovative Engineering and Management Research, 14(3), 301–312.
10. Santthosh Saai Reddy Purmani. (2026). Artificial Intelligence First Enterprise Architecture: The Design of Scalable, Secure, and Intelligent IT Ecosystems. American Journal of AI Cyber Computing Management, 6(1(2)), 1–8. [https://doi.org/10.64751/ajacm.2026.v6.n1\(2\).pp1-8](https://doi.org/10.64751/ajacm.2026.v6.n1(2).pp1-8)
11. Kotte, G. (2025). Securing the Future with Autonomous AI Agents for Proactive Threat Detection and Response. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5283830>
12. Purmani, S. S. R. (2025). Streamlining IT operations and service management with agile frameworks. European Journal of Advances in Engineering and Technology, 12(4), 76–81.
13. Mudusu, S. K. (2025). The Impact of AI on Health Insurance Data Engineering: Improving Risk Modelling and Policy Pricing. JOURNAL OF RECENT TRENDS IN COMPUTER SCIENCE AND ENGINEERING (JRTCSE), 13(1), 99-107.



14. Kotte, G. (2025). Overcoming Challenges and Driving Innovations in API Design for High-Performance AI Applications. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5283649>
15. Maturi, S. Y. (2023). Crowdsourced frontier: Unveiling autonomous adversarial cybercapabilities via open AI competition. *International Journal of Intelligent Systems and Applications in Engineering*, 11(1s), 275–284.
16. Purmani, S. S. R. (2025). Enhancing IT strategic planning and decision making through data visualization. *International Journal of Enhanced Research in Management & Computer Applications*, 14(4), 75–81
17. Maturi, S. Y. (2025). Vulnerabilities in the 802.11 Wireless Client Selection Mechanis.
18. Subramanian, V. K., Bhambri, S., & Gajula, S. (2025, April). Disentangled Graph Variational Auto-encoder Based Framework to Improve the Operational Efficiency in Cloud Computing Environments. In *International Conference on Computer Vision and Robotics* (pp. 396-407). Cham: Springer Nature Switzerland.
19. Kotte, G. (2025). Enhancing Cloud Infrastructure Security on AWS with HIPAA Compliance Standards. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5283660>
20. Maturi, S. Y. (2025). Blockbond Hardening: Securing Pooled-Hash Protocols Against Traffic Tampering, MITM Hash-Rate Hijacking, and Template Coercion. <https://doi.org/10.20944/preprints202512.2064.v1>
21. Mudusu, S. K., & Gentyala, S. (2026). Zero-Trust Data Pipelines for AI Systems: A Framework for Secure, Verifiable, and Auditable Data Engineering. *JOURNAL OF RECENT TRENDS IN COMPUTER SCIENCE AND ENGINEERING (JRTCSE)*, 14(2), 10-25.
22. Kotte, G. (2025). Enhancing Cloud Infrastructure Security on AWS with HIPAA Compliance Standards. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5283660>
23. Maturi, S. Y. Cryptographic Privacy Engines: Practical Multi-Party Protocols For Confidential Database Queries.
24. Gajula, S., Bondhala, S., & Margam, M. (2026, February). Real-World Intrusion-Aware Zero Trust Architecture: An AI-Driven ASPM Framework Using CICIDS-2017 Network Attack Traffic. In *2026 IEEE 5th International Conference on AI in Cybersecurity (ICAIC)* (pp. 1-7). IEEE.
25. Ranjbareslamloo, S., Dzukeya, G. A., Muhit, M. M. I., & Qattawi, A. (2025). Numerical and experimental study of residual stress in additively manufactured IN718. *Manufacturing Letters*, 44, 915–927. <https://doi.org/10.1016/j.mfglet.2025.915927>
26. Maturi, S. Y. Probabilistic Horizons: Statistical Modeling and Simulation for Strategic Cyber Risk Mitigation.
27. Mudusu, S. K. (2026, March 26). A data trust scoring framework for reliable and responsible AI systems. InfoWorld (Foundry Expert Contributor Network).
28. Kotte, G. (2025). Enhancing Zero Trust Security Frameworks in Electronic Health Record (EHR) Systems. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5283668>
29. Mudusu, S. (2025). Health Insurance Fraud Detection: The Role Of Advanced It Systems In Preventing And Identifying Fraud. *International Journal*, 16(1), 3769-3777



30. Kotte, G. (2025). Revolutionizing Stock Market Trading with Artificial Intelligence. SSRN Electronic Journal. <https://doi.org/10.2139/ssrn.5283647>
31. Maturi, S. Y. (2025). Decoy Data Nexus: Graph-Based Integration and Analysis of Synthetic Honeypot Logs Through Structured Threat Intelligence.
32. Sikder, M. Z., Shakil, M. A. I., Ahad, A., Karim, M. F., Intakhab, B., & Islam, D. A. (2025, June). Microwave-Based Detection of Early-Stage Renal Cell Carcinoma Using UHF Range Antenna. In 2025 International Conference on Computer Systems and Technologies (CompSysTech) (pp. 1-6). IEEE.
33. Mudusu, S. K. (2026, April 15). The secure intelligence framework: Architecting AI systems for a data-driven world. CIO (Foundry Expert Contributor Network).
34. Mahtabi, M., Roshan, M., Muhit, M. M. I., Behvar, A., & Haghshenas, M. (2026). Cryogenic ultrasonic fatigue: Mechanisms, advancements, and insights. *Cryogenics*, 153, 104257. <https://doi.org/10.1016/j.cryogenics.2025.104257>
35. Manoharan, D. (2026). AI-Driven Anomaly Detection Models for Preventing Claims Denials and Revenue Leakage in Healthcare. Available at SSRN 6385759.
36. Hassan, T., Karim, M. F., Jeelani, H., Behnam, E., Green, R., & Syed, F. J. (2025). Optimizing Medical Question-Answering Systems: A Comparative Study of Fine-Tuned and Zero-Shot Large Language Models with RAG Framework. arXiv preprint arXiv:2512.05863.
37. Gajula, S. (2025, December). Ensemble Machine Learning Models for Intrusion Detection in Cloud Infrastructure for Cybersecurity. In 2025 International Conference on Artificial Intelligence, Blockchain, Cloud Computing, and Data Analytics (ICoABCD) (pp. 1-6). IEEE.
38. Manoharan, D. (2026). Advancing Healthcare EDI Interoperability Through Informatica Cloud B2B Gateway Quality Engineering. Available at SSRN 6385719.
39. GIRISH KOTTE. (2025). ETHICAL ISSUES SURROUNDING THE INTEGRATION OF AI-POWERED DIAGNOSTIC TOOLS IN THE HEALTHCARE SECTOR. *American Journal of AI Cyber Computing Management*, 5(4), 329–334. <https://doi.org/10.64751/ajaccm.2025.v5.n4.pp329-334>
40. Chowdhury, A. K., Muhit, M. M. I., & Islam, M. M. (2023). A practical review to the marine maintenance practice in Bangladesh and a proposed way forward to an efficient, long-term and cost-effective solution. In Proceedings of the 13th International Conference on Marine Technology (MARTEC 2022). <https://doi.org/10.2139/ssrn.4445071>
41. Gajula, S., & Margam, M. (2026, February). A Secure and Scalable Cloud-Based Banking Service Model Leveraging AI and Advanced Cyber Security. In 2026 IEEE 5th International Conference on AI in Cybersecurity (ICAIC) (pp. 1-5). IEEE.
42. Mudusu, S. K. (2025). AI-driven data engineering in the Internet of Things: Scaling data pipelines for smart device ecosystems. *ISCSITR-International Journal of Data Engineering (ISCSITR-IJDE)*, 6(1), 1–9.
43. Gajula, S. (2025, December). Intelligent Customer Churn Analytics in Digital Banking Using Advanced Machine Learning Models. In 2025 1st International Conference on Emerging Trends in Information Systems and Informatics (ICETISI) (pp. 1-6). IEEE.
44. Manoharan, D. (2026). Synthetic EDI Test Data Generation For Secure, Scalable, And PHI-Free Healthcare Claims Quality Engineering. *Journal of International Crisis and Risk Communication Research*, 9(1).



International Journal of DATA SCIENCE AND IOT MANAGEMENT SYSTEM

Peer Reviewed, Referred & Indexed Journal

ISSN: 3068-272X

www.ijdim.com

Original Research Paper

45. Mudusu, S. K. (2026, February 9). AI-augmented data quality engineering. InfoWorld (Foundry Expert Contributor Network).
46. Gajula, S. (2025). Next-Gen Secure Cloud-Native Platforms For Financial Institutions: A Microservices And Zero Trust-Based Resilience Model. Journal of International Crisis & Risk Communication Research (JICRCR), 8.
47. Manoharan, D. (2025). Healthcare EDI Transaction Lifecycles Embedded with a Multi-Layer Verification Framework to Ensure Referential Integrity.
48. Mudusu, S. K. (2025, December 22). Cognitive data architecture: Designing self-optimizing frameworks for scalable AI systems. CIO (Foundry Expert Contributor Network).
49. Ranjbareslamloo, S., Dzukey, G. A., Islam Muhit, M. M., & Qattawi, A. (2025). Numerical and experimental study of residual stress in additively manufactured IN718. *Manufacturing Letters*, 44, 915–927. <https://doi.org/10.1016/j.mfglet.2025.06.108>
50. Manoharan, D. (2025). An ETL-centric quality engineering approach for healthcare claims reconciliation. *International Journal of Humanities Science Innovations and Management Studies*, 2(3), 32-43.
51. Gajula, S. (2026, March). Two Pillars of Banking Intelligence: A Comparative Analysis of AI Techniques for Fraud Prevention and Churn Mitigation. In 2026 14th International Symposium on Digital Forensics and Security (ISDFS) (pp. 1-6). IEEE.
52. Mudusu, S. K. (2025, June 3). Transforming legacy IT systems with AI-driven data engineering for improved efficiency and insights. *Hampton Global Business Review (HGBR)*.
53. Manoharan, D. (2024). Governance-Oriented Quality Engineering Framework for Healthcare EDI Modernization. *International Journal of Multidisciplinary on Science and Management IJMSM*, 1(2).
54. DEVARASETTY, N. (2023). SCALABLE DATA ENGINEERING APPROACHES FOR AI-DRIVEN INDUSTRIAL IOT APPLICATIONS. *INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND MANAGEMENT*, 11(06), 954-968.
55. Mudusu, S. K. (2025, April 20). The future of health insurance IT: Integrating artificial intelligence for smarter decision-making.
56. Agrawal, A. M., Gajula, S., Shinde, R. P., Shah, H., & Ghosh, H. (2025, July). Machine Translation for Long Sequences with Enhanced Attention Mechanisms. In 2025 5th International Conference on Electrical, Computer and Energy Technologies (ICECET) (pp. 1-6). IEEE.
57. Mudusu, S. K. (2025). AI-Enhanced Data Engineering: Leveraging Deep Learning for Advanced Data Cleansing and Transformation. *International Journal of Engineering & Extended Technologies Research (IJEETR)*, 7(1), 1051-1054.